argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

Summary

argenx presented new data on VYVGART at the AANEM and MGFA Scientific Session demonstrating earlier and sustained treatment benefits in MG and CIDP, along with progress updates across its neuromuscular pipeline.